By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Cellectis SA v. Precision BioSciences, Inc.
5:08-cv-00119; filed March 13, 2008 in the Eastern District of North Carolina
Infringement of U.S. Patent Nos. 7,309,605 ("Nucleotide Sequence Encoding the Enzyme I-SceI and the Uses Thereof," issued December 18, 2007) and 6,610,545 (same title, issued August 26, 2003), both licensed to Cellectis, based on Precision's use of its Directed Nuclease Editor technology. View the complaint here.
Wyeth v. Watson Laboratories Inc. et al.
1:08-cv-00145; filed March 12, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 6,500,814 ("Hormonal Contraceptive," issued December 31, 2002) following a paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Wyeth's Lybrel® (levonorgestrel/ethinyl estradiol, used as oral contraception). View the complaint here.
Sanofi-Aventis et al. v. Sandoz Inc.
2:08-cv-01190; filed March 7, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,514,531 ("Controlled-release Dosage Forms Comprising Zolpidem or a Salt Thereof," issued February 4, 2003) following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Sanofi-Aventis' Ambien CR® (controlled release zolpidem tartrate, used to treat insomnia). View the complaint here.
Pfizer Inc. et al. v. IMPAX Laboratories, Inc.
1:08-cv-02177; filed March 4, 2008 in the Southern District of New York
Infringement of U.S. Patent Nos. 5,382,600 ("3,3-Diphenylpropylamines and Pharmaceutical Compositions Thereof, issued January 17, 1995), 6,630,162 ("Pharmaceutical Formulation and Its Use," issued October 7, 2003), and 6,770,295 ("Therapeutic Formulation for Administering Tolterodine with Controlled Release," issued August 3, 2004) following a paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Pfizer's Detrol LA® (extended release tolterodine tartrate, used to treat overactive bladder). View the complaint here.
Pfizer Inc. et al. v. Gelfand
1:08-cv-02018; filed February 28, 2008 in the Southern District of New York
Declaratory judgment of non-infringement, unenforceabilty and/or invalidity of U.S. Patent No. 5,837,688 ("Use of Thrombolytic Reagents for Prevention of Vascular Disease," issued November 17, 1998) in conjunction with Pfizer's manufacture and sale of its Lipitor® (atorvastatin calcium, used to treat high cholesterol) and Caduet® (amlodipine and atorvastatin, used to treat high blood pressure and high cholesterol). View the complaint here.
Comments